These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37287306)

  • 1. Unlocking Delivery Strategies for mRNA Therapeutics.
    Luo Z; Chen Y
    Recent Pat Anticancer Drug Discov; 2024; 19(2):126-129. PubMed ID: 37287306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery.
    Kowalski PS; Rudra A; Miao L; Anderson DG
    Mol Ther; 2019 Apr; 27(4):710-728. PubMed ID: 30846391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivering the right message: Challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-An innate immune system standpoint.
    Granot Y; Peer D
    Semin Immunol; 2017 Dec; 34():68-77. PubMed ID: 28890238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mRNA delivery technologies: Toward clinical translation.
    Gómez-Aguado I; Rodríguez-Castejón J; Beraza-Millor M; Rodríguez-Gascón A; Del Pozo-Rodríguez A; Solinís MÁ
    Int Rev Cell Mol Biol; 2022; 372():207-293. PubMed ID: 36064265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering.
    Billingsley MM; Singh N; Ravikumar P; Zhang R; June CH; Mitchell MJ
    Nano Lett; 2020 Mar; 20(3):1578-1589. PubMed ID: 31951421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid Nanoparticle-mRNA Formulations for Therapeutic Applications.
    Wang C; Zhang Y; Dong Y
    Acc Chem Res; 2021 Dec; 54(23):4283-4293. PubMed ID: 34793124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
    Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Overview of Nanoparticle-Based Delivery Platforms for mRNA Vaccines for Treating Cancer.
    Lin Y; Chen X; Wang K; Liang L; Zhang H
    Vaccines (Basel); 2024 Jun; 12(7):. PubMed ID: 39066365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing.
    Qiu M; Li Y; Bloomer H; Xu Q
    Acc Chem Res; 2021 Nov; 54(21):4001-4011. PubMed ID: 34668716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vitro Engineering Chimeric Antigen Receptor Macrophages and T Cells by Lipid Nanoparticle-Mediated mRNA Delivery.
    Ye Z; Chen J; Zhao X; Li Y; Harmon J; Huang C; Chen J; Xu Q
    ACS Biomater Sci Eng; 2022 Feb; 8(2):722-733. PubMed ID: 35104103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Materials for non-viral intracellular delivery of messenger RNA therapeutics.
    Kauffman KJ; Webber MJ; Anderson DG
    J Control Release; 2016 Oct; 240():227-234. PubMed ID: 26718856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticles for nucleic acid delivery: Applications in cancer immunotherapy.
    Mukalel AJ; Riley RS; Zhang R; Mitchell MJ
    Cancer Lett; 2019 Aug; 458():102-112. PubMed ID: 31100411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoscale platforms for messenger RNA delivery.
    Li B; Zhang X; Dong Y
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Mar; 11(2):e1530. PubMed ID: 29726120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
    Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
    Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Status of Messenger RNA Delivery Systems.
    Stanton MG
    Nucleic Acid Ther; 2018 Jun; 28(3):158-165. PubMed ID: 29688817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pieter Cullis' quest for a lipid-based, fusogenic delivery system for nucleic acid therapeutics: success with siRNA so what about mRNA?
    Tam YK; Madden TD; Hope MJ
    J Drug Target; 2016 Nov; 24(9):774-779. PubMed ID: 27588674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research advance in lipid nanoparticle-mRNA delivery system and its application in CAR-T cell therapy.
    Ye B; Hu Y; Zhang M; Huang H
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):185-191. PubMed ID: 36161298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current landscape of mRNA technologies and delivery systems for new modality therapeutics.
    Lu RM; Hsu HE; Perez SJLP; Kumari M; Chen GH; Hong MH; Lin YS; Liu CH; Ko SH; Concio CAP; Su YJ; Chang YH; Li WS; Wu HC
    J Biomed Sci; 2024 Sep; 31(1):89. PubMed ID: 39256822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticle technology for mRNA: Delivery strategy, clinical application and developmental landscape.
    Li X; Qi J; Wang J; Hu W; Zhou W; Wang Y; Li T
    Theranostics; 2024; 14(2):738-760. PubMed ID: 38169577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and applications of mRNA treatment based on lipid nanoparticles.
    Wang Z; Ma W; Fu X; Qi Y; Zhao Y; Zhang S
    Biotechnol Adv; 2023; 65():108130. PubMed ID: 36933868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.